Related references
Note: Only part of the references are listed.A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin-Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel in Early-Stage Breast Cancer
Heather L. McArthur et al.
CLINICAL CANCER RESEARCH (2011)
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
Thomas Force et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Molecular Mechanisms of Hypertension and Heart Failure Due to Antiangiogenic Cancer Therapies
Meredith L. Rees et al.
HEART FAILURE CLINICS (2011)
Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics
Hui Cheng et al.
CIRCULATION RESEARCH (2010)
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor-Signaling Inhibitors
Emily S. Robinson et al.
HYPERTENSION (2010)
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Suzanne E. Dahlberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Michael L. Maitland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment
Michael L. Maitland et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib-Induced Cardiotoxicity Is Mediated by Off-Target Inhibition of AMP-Activated Protein Kinase
Risto Kerkela et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2009)
Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors
Vishnu Chintalgattu et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2009)
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
Carie S. Facemire et al.
HYPERTENSION (2009)
Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
Marlies H. G. Langenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition
Pamela H. Franklin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Kamran Ghoreschi et al.
NATURE IMMUNOLOGY (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
J. -J. Mourad et al.
ANNALS OF ONCOLOGY (2008)
Inhibition of vascular endothelial growth factor-A signaling induces hypertension: Examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant anti hypertensive therapy
Jon O. Curwen et al.
CLINICAL CANCER RESEARCH (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Home blood-pressure monitoring in patients receiving sunitinib
Michel Azizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR. 20
Andrew M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20
A. M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Share Paper
